On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported upbeat second-quarter earnings.
The company posted adjusted earnings of $12.89 per share, up 12% year-over-year, beating the consensus of $8.57. The company reported sales of $3.68 billion, up 4% year over year, beating the consensus of $3.29 billion.
Regeneron expects a 2025 GAAP gross margin of approximately 83%, compared to the prior guidance of 83%–84%. The company expects an adjusted gross margin of approximately 86%, compared to the prior guidance of 86%–87%.
“Regeneron had a strong quarter, marked by significant growth in U.S. sales of EYLEA HD and global …